Vanguard Group’s Neumora Therapeutics NMRA Stock Holding History

Vanguard Group’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$8.13M	Buy	4,539,261 +490,094	+12%	+$1.07M	﹤0.01%	3068
2025 Q3	$7.37M	Sell	4,049,167 -713,736	-15%	-$1.15M	﹤0.01%	3136
2025 Q2	$3.49M	Sell	4,762,903 -562,134	-11%	-$426K	﹤0.01%	3330
2025 Q1	$5.33M	Buy	5,325,037 +752,729	+16%	+$1.29M	﹤0.01%	3145
2024 Q4	$48.5M	Buy	4,572,308 +195,142	+4%	+$2.34M	﹤0.01%	2170
2024 Q3	$57.8M	Buy	4,377,166 +1,103,042	+34%	+$12.9M	﹤0.01%	2118
2024 Q2	$32.2M	Buy	3,274,124 +2,939,794	+879%	+$30.4M	﹤0.01%	2333
2024 Q1	$4.6M	Sell	334,330 -46,624	-12%	-$754K	﹤0.01%	3334
2023 Q4	$6.5M	Buy	380,954 +330,954	+662%	+$4.06M	﹤0.01%	3181
2023 Q3	$706K	Buy	+50,000	New	+$625K	﹤0.01%	3951

Other funds holding NMRA

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group's NMRA Position: Q4 2025 in Review

Vanguard Group increased its Neumora Therapeutics (NMRA) stake by 12% in Q4 2025, buying an estimated $1.07M and bringing the position to 4,539,261 shares worth $8.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3068.

Vanguard Group first reported a position in NMRA in Q3 2023 and has held it in 10 quarters since. The position peaked at $57.8M in Q3 2024. 102 funds tracked by Wall St. Rank hold NMRA as of Q4 2025.

Vanguard Group held 4,539,261 shares of Neumora Therapeutics worth $8.13M as of Q4 2025.
Vanguard Group bought 490,094 Neumora Therapeutics shares in Q4 2025, an estimated $1.07M.
Neumora Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3068 holding.
Vanguard Group first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 10 quarters since.
Vanguard Group's Neumora Therapeutics position peaked at $57.8M in Q3 2024.
102 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.